Clinical Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nathan, C.-A. O.
Right arrow Articles by Glass, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathan, C.-A. O.
Right arrow Articles by Glass, J.
Clinical Cancer Research Vol. 10, 5820-5827, September 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Overexpressed eIF4E Is Functionally Active in Surgical Margins of Head and Neck Cancer Patients via Activation of the Akt/Mammalian Target of Rapamycin Pathway

Cherie-Ann O. Nathan, Nazanin Amirghahari, Fleurette Abreo, Xiaohua Rong, Gloria Caldito, M. Lamar Jones, Huijuan Zhou, Melanie Smith, Donnellan Kimberly and Jonathan Glass

Louisiana State University Health Sciences Center, Feist-Weiller Cancer Center and the Veterans Administration, Shreveport, Louisiana

Purpose: Overexpression of eIF4E in surgical margins of head and neck cancer patients is an independent risk factor for recurrence. We hypothesize that overexpressed eIF4E is functionally active in tumor margins through activation of the Akt/mammalian target of rapamycin (mTOR) pathway

Experimental Design: Western blots and/or immunohistochemistry were performed to determine whether phosphorylation of mTOR and activation of its downstream molecules eIF4E-binding protein-1 (4E-BP1) and p70 S6 kinase and the upstream modulator of mTOR, Akt, were expressed in margins overexpressing eIF4E.

Results: There was a significant association between phospho-4E-BP1 and eIF4E expression of a margin or a significant difference in phospho-4E-BP1 expression between the eIF4E-positive and -negative margins (P < 0.01). A significant association between eIF4E and phospho-p70 S6 kinase as well as eIF4E and phospho-mTOR was also noted (P < 0.05). Western blot analysis indicated a highly significant difference in the phosphorylation status of 4E-BP1 between tumors and resection margins. A total of 89% of the 4E-BP1-expressing margins expressed more of the phosphorylated (ß, {gamma}, and {delta}) isoforms, whereas 81% of the 4E-BP1-expressing tumors expressed more of the unphosphorylated {alpha} isoform. A similar difference in Akt activation was noted between eIF4E-positive margins and tumors (P < 0.05).

Conclusions: Overexpression of eIF4E is functionally active in tumor margins through activation of the Akt/mTOR signaling pathway. The greater degree of expression of downstream targets and upstream regulators of mTOR in margins compared with the tumors indicates preferential activation of the Akt/mTOR signaling pathway in margins overexpressing eIF4E. Rapamycin analogs can potentially be used as adjuvant therapy for patients with eIF4E-positive margins.




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
J Boone, F J W T. Kate, G J A Offerhaus, P J van Diest, I H M B. Rinkes, and R van Hillegersberg
mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?
J. Clin. Pathol., August 1, 2008; 61(8): 909 - 913.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Khan, F. Afaq, M.-H. Kweon, K. Kim, and H. Mukhtar
Oral Consumption of Pomegranate Fruit Extract Inhibits Growth and Progression of Primary Lung Tumors in Mice
Cancer Res., April 1, 2007; 67(7): 3475 - 3482.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-A. O. Nathan, N. Amirghahari, X. Rong, T. Giordano, D. Sibley, M. Nordberg, J. Glass, A. Agarwal, and G. Caldito
Mammalian Target of Rapamycin Inhibitors as Possible Adjuvant Therapy for Microscopic Residual Disease in Head and Neck Squamous Cell Cancer
Cancer Res., March 1, 2007; 67(5): 2160 - 2168.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M.-H. Yang, W.-C. Chiang, T.-Y. Chou, S.-Y. Chang, P.-M. Chen, S.-C. Teng, and K.-J. Wu
Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation
Clin. Cancer Res., January 15, 2006; 12(2): 507 - 515.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.